Zentalis Pharmaceuticals (NASDAQ:ZNTL) Given Buy Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) in a research report sent to investors on Monday morning,Benzinga reports. They currently have a $10.00 price objective on the stock.

A number of other brokerages have also recently issued reports on ZNTL. Wedbush restated a “neutral” rating and set a $4.00 target price on shares of Zentalis Pharmaceuticals in a research report on Friday, January 24th. UBS Group cut their price objective on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Finally, Wells Fargo & Company cut their price objective on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a research report on Thursday, January 30th. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $8.24.

Zentalis Pharmaceuticals Trading Up 6.8 %

ZNTL stock opened at $1.89 on Monday. The company has a market cap of $134.69 million, a P/E ratio of -0.76 and a beta of 1.75. Zentalis Pharmaceuticals has a 52 week low of $1.61 and a 52 week high of $16.27. The company’s 50-day moving average price is $2.19 and its 200 day moving average price is $2.94.

Insider Activity at Zentalis Pharmaceuticals

In other Zentalis Pharmaceuticals news, Director Jan Skvarka purchased 60,000 shares of Zentalis Pharmaceuticals stock in a transaction dated Friday, January 31st. The shares were bought at an average cost of $1.72 per share, for a total transaction of $103,200.00. Following the transaction, the director now owns 149,551 shares in the company, valued at $257,227.72. This represents a 67.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Ingmar Bruns purchased 20,000 shares of Zentalis Pharmaceuticals stock in a transaction dated Thursday, February 6th. The stock was acquired at an average price of $2.28 per share, for a total transaction of $45,600.00. Following the completion of the transaction, the insider now owns 36,629 shares in the company, valued at approximately $83,514.12. The trade was a 120.27 % increase in their position. The disclosure for this purchase can be found here. 3.60% of the stock is currently owned by corporate insiders.

Institutional Trading of Zentalis Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Barclays PLC increased its stake in Zentalis Pharmaceuticals by 18.5% during the 3rd quarter. Barclays PLC now owns 75,395 shares of the company’s stock valued at $277,000 after buying an additional 11,748 shares during the period. Verition Fund Management LLC increased its stake in Zentalis Pharmaceuticals by 172.1% during the 3rd quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company’s stock valued at $5,536,000 after buying an additional 951,500 shares during the period. Primecap Management Co. CA increased its stake in Zentalis Pharmaceuticals by 21.6% during the 3rd quarter. Primecap Management Co. CA now owns 1,498,030 shares of the company’s stock valued at $5,513,000 after buying an additional 265,690 shares during the period. SG Americas Securities LLC increased its stake in Zentalis Pharmaceuticals by 115.6% during the 4th quarter. SG Americas Securities LLC now owns 56,389 shares of the company’s stock valued at $171,000 after buying an additional 30,240 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. increased its stake in Zentalis Pharmaceuticals by 126.3% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 229,138 shares of the company’s stock valued at $843,000 after buying an additional 127,868 shares during the period.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.